PaxMedica Future Growth
Future criteria checks 0/6
PaxMedica's earnings are forecast to decline at 61.5% per annum. EPS is expected to grow by 131.4% per annum.
Key information
-61.5%
Earnings growth rate
131.4%
EPS growth rate
| Pharmaceuticals earnings growth | 19.6% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 04 Dec 2023 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2024 | N/A | -12,204 | N/A | -6,204 | 1 |
| 12/31/2023 | N/A | -16,170 | N/A | -10,652 | 1 |
| 9/30/2023 | N/A | -18 | -11 | -11 | N/A |
| 6/30/2023 | N/A | -23 | -10 | -10 | N/A |
| 3/31/2023 | N/A | -20 | -9 | -9 | N/A |
| 12/31/2022 | N/A | -15 | -6 | -6 | N/A |
| 9/30/2022 | N/A | -3 | -4 | -4 | N/A |
| 6/30/2022 | N/A | 4 | -4 | -4 | N/A |
| 3/31/2022 | N/A | -2 | -5 | -5 | N/A |
| 12/31/2021 | N/A | -10 | -6 | -6 | N/A |
| 9/30/2021 | N/A | -21 | -6 | -6 | N/A |
| 6/30/2021 | N/A | -21 | -5 | -5 | N/A |
| 3/31/2021 | N/A | -16 | -3 | -3 | N/A |
| 12/31/2020 | N/A | -9 | -2 | -2 | N/A |
| 6/30/2020 | N/A | -2 | -1 | -1 | N/A |
| 3/31/2020 | N/A | -1 | 0 | 0 | N/A |
| 12/31/2019 | N/A | -1 | 0 | 0 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PXMD * is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: PXMD * is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: PXMD * is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if PXMD *'s revenue is forecast to grow faster than the MX market.
High Growth Revenue: PXMD * is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PXMD *'s Return on Equity is forecast to be high in 3 years time